Flythe JE, Forfang D, Gedney N, White DM, Wilkie C, Cavanaugh K, Harris RC, Unruh M, Squillaci G, West M, Mansfield C, Soloe CS, Treiman K, Wood D, Hurst FP, Neuland C, Saha A, Sheldon M, Tarver ME. Development of a patient preference survey for wearable kidney replacement therapy devices. Kidney360. 2022 May 5;3(7):1197-209. doi: 10.34067/KID.0001862022
Anderson S, Mauskopf J, Talbird SE, White A, Meenakshi S. Antiseizure medications and oral contraceptives: impact of enzyme inducers on pregnancy outcomes and costs. Epilepsy Behav. 2021 Dec;125:108368. doi: 10.1016/j.yebeh.2021.108368
Farreny A, Aguado J, Ochoa S, Haro JM, Usall J. The role of negative symptoms in the context of cognitive remediation for schizophrenia. Schizophr Res. 2013 Oct;150(1):58-63.
Farreny A, Aguado J, Ochoa S, Huerta-Ramos E, Marsà F, López-Carrilero R, Carral V, Haro JM, Usall J. REPYFLEC cognitive remediation group training in schizophrenia: looking for an integrative approach. Schizophr Res. 2012 Dec;142(1-3):137-44. doi: 10.1016/j.schres.2012.08.035.
Graham CN, Mauskopf J, Lawson AH, Ascher-Svanum H, Bruhn D, Watson PR. Validating an industry-sponsored model comparing the cost-effectiveness of atypical antipsychotics in the treatment of schizophrenia. Schizophr Res. 2010 Apr 1;117(2-3):398-9.
Ettinger AB, Manjunath R, Candrilli SD, Davis KL. Prevalence and cost of nonadherence with antiepileptic drugs in elderly patients with epilepsy. Epilepsy Behav. 2009 Feb;14(2):324-9. doi: 10.1016/j.yebeh.2008.10.021.
Manjunath RY, Davis KL, Candrilli SD, Ettinger AE. Association of antiepileptic drug nonadherence with risk of seizures in adults with epilepsy. Epilepsy Behav. 2009 Jan;14(2):372-8.
French M, Neighbors D, Carswell L, Williams R, Bush L. A model for estimating industry compliance costs of food labeling regulations. Agribusiness: An International Journal. 1993;8(2):165-86.